Recombinant human erythropoietin (Center of Molecular Immunology)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human erythropoietin (Center of Molecular Immunology)
Drug Alias NameiorEPOCIMNeuroEPO (nasal)1-165-Erythropoietin (human clone lambdaHEPOFL13 protein moiety), glycoform alphaNeuroEPOIor
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsAnemia, AplasticAlzheimer Disease
Global Approved IndicationsAnemia, Aplastic
Approved Indications in ChinaN/A
Original Approved Country/TerritoryCuba
Original Approved Date1998/04/01
Country/TerritoryCanadaCuba
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCenter Of Molecular Immunology
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsAnemia, AplasticAlzheimer Disease
Inactive IndicationsN/A

Other Information

ATC CodeB03XA01
Related LinksN/A